Exane BNP Paribas announced AstraZeneca PLC (LON:AZN), upholding its stock price target at 5,200.00GBX today
- Updated: September 29, 2016
In a report released on 9/30/2016 Exane BNP Paribas hold steady the stock price target of AstraZeneca PLC (LON:AZN) from 5,200.00GBX to 5,200.00GBX indicating a possible upside of 0.05%.
Yesterday AstraZeneca PLC (LON:AZN) traded -1.00% lower at 4,972.75GBX. The company’s 50-day moving average is 5,019.33GBX and its 200-day moving average is 4,394.52GBX. The last stock close price is up 13.22% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 402,435 shares of the stock were exchanged, down from an avg. volume of 2,669,960
With a total market value of 0 GBX, AstraZeneca PLC has price-earnings ratio of 28.43 with a one year low of 3,680.00GBX and a one year high of 5,505.00GBX .
A total of 29 analysts have released a research note on AstraZeneca PLC. Four analysts rating the company a strong buy, fourteen analysts rating the company a buy, thirteen analysts rating the company a hold, two analysts rating the company a underperform, and finally one analyst rating the company a sell with a 12-month price target of 61.96GBX.
More About AstraZeneca PLC (LON:AZN)
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. The Company has its operations in over 100 countries. The Company's pipeline includes over 150 projects of which approximately 125 are in the clinical phase of development. The Company is developing a Toll-like receptor 9 (TLR-9) receptor agonist aimed at producing long-term benefit in asthma by addressing imbalances in the immune system. AstraZeneca offers various products, including Accolate, Rhinocort, Bricanyl Turbuhaler, Rhinocort, Symbicort pMDI, Crestor, Seloken/Toprol-XL, Brilinta/Brilique (ticagrelor), Bydureon, Xigduo XR, Kombiglyze XR and metformin XR, among others.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.